Drug combination shows promise for mitigating microbial biofilms
28 October 2024
Combining allicin with domiphen could reduce biofilm formation, providing a potential avenue for overcoming antimicrobial resistance, research suggests.
Over two years, Moscow supported 100 projects for clinical trials of drugs
28 October 2024
Saint Petersburg State Chemical Pharmaceutical University plans mass production of three innovative drugs based on original molecular compounds. Information about this was provided by Sergey Okovity, head of the Department of Pharmacology and Clinical Pharmacology. Currently, the institution is in discussions with five prominent domestic pharmaceutical manufacturers regarding collaborative funding for the second and third phases of clinical trials, as well as establishing the production proc
A special program in Moscow led to 100 clinical drug trial projects over two years, involving 23 Russian and foreign companies, according to Deputy Mayor Anastasia Rakova. She noted that the ecosystem established in the capital, centered around a communication hub, has effectively supported research across 15 therapeutic areas. As part of the program, a total of 36 studies focused on bioanalogs and generics, 50 studies dedicated to original drugs, and 14 studies oriented toward vaccines were initiated.
ess.
In 2023 Russia registered 56 drugs and 206 medical devices for cardiovascular diseases.
25 October 2024
In 2023, Russia registered 56 generic drugs specifically designed to treat cardiovascular diseases, along with 206 essential medical devices for individuals suffering from these conditions. The Deputy Minister of Health of the Russian Federation, Sergei Glagolev, presented this data during a meeting of the State Duma Committee on Health Protection.
Payments to doctors for cancer alertness will continue through 2027
25 October 2024
The State Duma adopted a bill to extend inter-budget transfers to health insurance funds in 2027 to address personnel shortages and reward early cancer detection by health workers. “The changes provided for by the bill are aimed at increasing the efficiency of using compulsory medical insurance funds and providing medical care,” the explanatory note to the draft states.
The Russian Ministry of Health initiates the creation of a list of key drugs
24 October 2024
The Russian Ministry of Health has proposed an initiative to define specific criteria for creating a list of strategically important medications. This list is planned to be compiled on the basis of the existing list of vital and essential drugs. The key condition for inclusion in the list of key drugs is a full production cycle of the drug in Russia.
First stage of clinical trial of new Russian anti-cancer drug completed
24 October 2024
The Institute of Chemical Biology and Fundamental Medicine of the Siberian Branch of the RAS, ICBFM SB RAS reported the successful completion of the first phase of clinical trials of the domestic antitumor drug VV-GMCSF-Lact. They confirmed the safety of the drug and its effectiveness in the fight against breast tumors. The drug was developed by the Institute, the Vector Center and Oncostar LLC.
Federal Center for Animal Health develops 13 new veterinary vaccines
22 October 2024
The Federal State-Financed Institution “Federal Centre for Animal Health” (ARRIAH), part of the Federal Service for Veterinary and Phytosanitary Surveillance (Rosselkhoznadzor) is working to expand the range of vaccines for various animal species. Deputy Director for Research Ilya Chvala shared information about the institute’s current developments in an interview with the Agroexpert publication.
Haemophilia treatment with new delivery method approved
22 October 2024
The first anti-tissue factor pathway inhibitor (anti-TFPI) treatment for haemophilia A or B in the US has been approved by the US Food and Drug Administration (FDA). Hympavzi (marstacimab-hncq) is authorised for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in individuals 12 years of age and over with haemophilia A or haemophilia B without inhibitors.
Immunotherapy treatment enhances lymphoma survival, landmark study shows
21 October 2024
The Phase III findings give evidence for the immunotherapy treatment regimen to become standard of care for advanced Hodgkin lymphoma. A new immunotherapy treatment regimen (nivolumab plus doxorubicin, vinblastine, and dacarbazine (AVD)) provided a significant survival rate in advanced Hodgkin lymphoma patients, Phase III trial data shows.
The Russian Ministry of Health initiates the creation of a list of key drugs
21 October 2024
The Russian Ministry of Health has proposed an initiative to define specific criteria for creating a list of strategically important medications. This list is planned to be compiled on the basis of the existing list of vital and essential drugs. The key condition for inclusion in the list of key drugs is a full production cycle of the drug in Russia.
05 November 2024
03 November 2024
October 10 – World Mental Health Day
10 October 2024
Innovative method could address a major limitation in fluorescence microscopy
26 November 2024
Virtual Patients, Real Results: How Digital Twins Are Reshaping Drug Development
26 November 2024
news Innovating LNP design to improve mRNA therapeutics
25 November 2024
Siberian State Medical University and Skoltech to start production of bone tissue fillers
25 November 2024